Positron Emission Tomography with Pittsburgh Compound B in Diagnosis of Early Stage Alzheimer's Disease

Cell Biochemistry and Biophysics

Volumn 59, Issue 1, 2011, Pages 57-62

  Jia, Jianjun ^a   Sun, Binbin ^b   Guo, Zhe ^a   Zhang, Jinming ^a   Tian, Jiahe ^a   Tang, Hongchuan ^a   Wang, Luning ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Alzheimer's disease; Mild cognitive impairment; Pittsburgh compound B; Positron emission tomography; amyloid

Indexed keywords

EID: 78650415960     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-010-9111-2     Document Type: Article

References (19)

1. Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., et al. (2007). Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology, 29, 125-132.
2. Hardy, J. A., & Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science, 256, 184-185.
3. Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., et al. (1991). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology, 41, 479-486.
4. Portet, F., Ousset, P. J., Visser, P. J., Frisoni, G. B., Nobili, F., Scheltens, P., et al. (2006). Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. Journal of Neurology, Neurosurgery and Psychiatry, 77, 714-718.
5. Levey, A., Lah, J., Goldstein, F., Steenland, K., & Bliwise, D. (2006). Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clinical Therapeutics, 28, 991-1001.
6. Kemppainen, N. M., Aalto, S., Wilson, I. A., Nagren, K., Helin, S., Bruck, A., et al. (2007). PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology, 68, 1603-1606.
7. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
8. Lichtenstein, M. J., & Schaffner, W. (1985). Assessing activities of daily living. Hospital Practice (Office Edition), 20, 8-9.
9. Mok, E. H., Lam, L. C., & Chiu, H. F. (2004). Category verbal fluency test performance in Chinese elderly with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 18, 120-124.
10. Mountjoy, C. Q. (1988). Dementia and the Hachinski Scale. British Journal of Hospital Medicine, 39, 254.
11. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, 6, 734-746.
12. Price, J. L., & Morris, J. C. (1999). Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Annals of Neurology, 45, 358-368.
13. Silverman, D. H., Truong, C. T., Kim, S. K., Chang, C. Y., Chen, W., Kowell, A. P., et al. (2003). Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Molecular Genetics and Metabolism, 80, 350-355.
14. Weaver, J. D., Espinoza, R., & Weintraub, N. T. (2007). The utility of PET brain imaging in the initial evaluation of dementia. Journal of the American Medical Directors Association, 8, 150-157.
15. Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., et al. (2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology, 68, 501-508.
16. Mathis, C. A., Wang, Y., Holt, D. P., Huang, G. F., Debnath, M. L., & Klunk, W. E. (2003). Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. Journal of Medicinal Chemistry, 46, 2740-2754.
17. Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., et al. (2009). Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiology of Diseases, 34, 107-112.
18. Rabinovici, G. D., Furst, A. J., O'Neil, J. P., Racine, C. A., Mormino, E. C., Baker, S. L., et al. (2007). 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology, 68, 1205-1212.
19. Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., et al. (2007). PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain, 130, 2607-2615.